PUBLISHER: DataM Intelligence | PRODUCT CODE: 1297815
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1297815
Global Endometrial Cancer Market - 2023-2030
Market Overview
The Global Endometrial Cancer Market reached US$ 18.7 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 27.3 billion by 2030. The global endometrial cancer market is expected to exhibit a CAGR of 4.9% during the forecast period (2023-2030).
The key market players in this market include Pfizer, AbilityPharma (Ability Pharmaceuticals, SL), and GlaxoSmithKline among others.
Market Dynamics
Increasing Research Activities Drive The Growth Of The Endometrial Cancer Market.
Increasing product approvals are expected to drive the global Endometrial Cancers market growth in the forecast period. For instance, in February 2023, the European Commission conditionally authorized Hemgenix (etranacogene dezaparvovec), a one-time gene therapy indicated for the treatment of adults with hemophilia B. Hemgenix, primarily designed by uniQure, authorized for adults with extreme and relatively extreme hemophilia B without a record of inhibitors. It's the foremost gene treatment for hemophilia B known to patients throughout all European Union member states, plus Iceland, Liechtenstein, and Norway.
Moreover, in February 2023, Roche, a Swiss global healthcare corporation acquired the European Commission and consent for the expansion of the Hemlibra (emicizumab) European Union (EU) marketing authorization. The label is expected to currently contain the standard prophylaxis of bleeding outbreaks in individuals with hemophilia A without factor VIII inhibitors, who have mild conditions with an extreme bleeding phenotype.
The Increasing Efforts To Spread Awareness Are Expected To Present The Global Endometrial Cancer Market With Growth Opportunities.
The increasing research funding initiatives are expected to present global endomertial cancer with lucrative growth opportunities in the upcoming years. For instance, on June 1, 2023, the International Gynecologic Cancer Society and its patient advocacy associate, the International Gynecologic Cancer Advocacy Network (IGCAN) with help from patient advocacy organizations all over the globe announced its determination to raise awareness of uterine and endometrial cancer through various campaigns.
The High Cost of Treatment Is Estimated To Hamper The Global Endometrial Cancer Market During The Forecast Period.
The high cost of treatment is estimated to hamper the global endometrial cancer market growth in the forecast period. For instance, the cost of uterine cancer therapy in India varies from US$ 4000 - US$ 6000 based on the grade of therapy and the hospital.
COVID-19 Impact Analysis
The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.
Russia-Ukraine War Impact Analysis
The Russia-Ukraine war is considered to carry a moderate mark on the global endometrial cancer market, as the low prevalence and dearth of critical market players in this region. Yet, persisting to countenance raids from Russian troops, Ukrainian infirmaries are pushed by increasing numerals of deaths and specified medical aids. There are deficiencies across all kinds of drugs. Again, the consequence of the import and export of fundamental materials are predicted to have a small influence on the global endometrial cancer market growth in the forecast period.
Segment Analysis
The global endometrial cancer market is segmented based on type, therapy type, end-user and region.
Owing To The Increasing Positive Outcomes From The Immunotherapy Clinical Investigations The Segment Is Estimated To Hold About 34.9% Of The Global Market Share By 2030.
Immunotherapy for uterine (endometrial) cancer is an emerging domain of investigation and therapy, particularly for individuals with advanced cases. The increasing positive outcomes from immunotherapy for endometrial cancer are boosting segment growth. For instance, in March 2023, implementing immunotherapy to classic chemotherapy for first-line therapy of progressive or first repetition of endometrial cancer greatly enhances progression-free survival (PFS) analogized to chemotherapy independently, with a favorable premature sign of enhanced overall survival (OS). These clinically significant outcomes from the Phase 3 RUBY investigation (ENGOT-EN6-NSGO/GOG3031) are the foremost validation of the advantages of immunotherapy in this patient population and were conveyed at the European Society for Medical Oncology Virtual Plenary on 27 March 2023.
Geographical Analysis
Europe Estimated to Hold 27.4% of the Market Share Owing to the Growing Endometrial Cancer Prevalence in this Region.
Owing to the growing cases of uterine cancers and the presence of various organizations spreading awareness and funding research activities in uterine cancer in Europe, the region is estimated to hold the second largest share of the global market accounting for about 27.4% of the total market. For instance, uterine cancer is the fourth highly typical cancer in females in the UK, accounting for 5% of all new gynecological cancer patients. About 9,400 fresh patients are analyzed annually, leading to the death of 2,300 females. The majority of cases appear in the seventh and eighth decades of life. Since the earlier 1990s, the incidence of uterine cancer has grown by 55% in the UK.
Moreover, associations like GRACE Charity desire to support the locally founded investigation into gynecological cancers such as ovarian, uterine, cervical, and vulvar cancer, primarily at the University of Surrey in Guildford, and within the Gynecology Department and spreading awareness about the condition are also contributing to the growth.
Competitive Landscape
The major global players in the endometrial cancer market include: Pfizer, AbilityPharma (Ability Pharmaceuticals, SL), Elekta AB, GlaxoSmithKline, Eisai Co., Ltd., ARIAD Pharmaceuticals, Novartis, AstraZeneca PLC, Karyopharm Therapeutics, and Bayer AG among others.
Why Purchase the Report?
- To visualize the global endometrial cancer market segmentation based on type, therapy type, end-user and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of endometrial cancer market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The global endometrial cancer market report would provide approximately 53 tables, 54 figures and 195 pages.
Target Audience 2023
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
Table of Contents
1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
- 3.1. Snippet by Type
- 3.2. Snippet by Therapy Type
- 3.3. Snippet by End-user
- 3.4. Snippet by Region
4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Increasing Research Activities
- 4.1.1.2. Growing Prevalence
- 4.1.2. Restraints
- 4.1.2.1. High Cost
- 4.1.3. Opportunity
- 4.1.3.1. Growing Awareness
- 4.1.4. Impact Analysis
- 4.1.1. Drivers
5. Industry Analysis
- 5.1. Porter's 5 Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion
7. By Type
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 7.1.2. Market Attractiveness Index, By Type
- 7.2. Carcinosarcoma *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Adenocarcinoma
- 7.4. Squamous cell Carcinoma
- 7.5. Others
8. By Therapy Type
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 8.1.2. Market Attractiveness Index, By Therapy Type
- 8.2. Immunotherapy *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Chemotherapy
- 8.4. Radiation Therapy
- 8.5. Others
9. By End-user
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 9.1.2. Market Attractiveness Index, By End-user
- 9.2. Hospitals *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Cancer Centers
- 9.4. Others
10. By Region
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
- 10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.2.6.1. The U.S.
- 10.2.6.2. Canada
- 10.2.6.3. Mexico
- 10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.3.6.1. Germany
- 10.3.6.2. The U.K.
- 10.3.6.3. France
- 10.3.6.4. Spain
- 10.3.6.5. Italy
- 10.3.6.6. Rest of Europe
- 10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.4.6.1. Brazil
- 10.4.6.2. Argentina
- 10.4.6.3. Rest of South America
- 10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 10.5.6.1. China
- 10.5.6.2. India
- 10.5.6.3. Japan
Australia
- 10.5.6.4. Rest of Asia-Pacific
- 10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
11. Competitive Landscape
- 11.1. Competitive Scenario
- 11.2. Market Positioning/Share Analysis
- 11.3. Mergers and Acquisitions Analysis
12. Company Profiles
- 12.1. Pfizer*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
- 12.2. Elekta AB
- 12.3. AstraZeneca PLC
- 12.4. AbilityPharma (Ability Pharmaceuticals, SL)
- 12.5. GlaxoSmithKline
- 12.6. Eisai Co., Ltd
- 12.7. ARIAD Pharmaceuticals
- 12.8. Novartis
- 12.9. Karyopharm Therapeutics
- 12.10. Bayer AG
LIST NOT EXHAUSTIVE
13. Appendix
- 13.1. About Us and Services
- 13.2. Contact Us
